As the population ages, vaccinations become even more valuable by helping Australians to live well for longer. Preventing disease is integral to Australia’s future economic resilience, as a healthy ageing population positively impacts workforce productivity, participation, and economic growth.
Prevention: A Productivity Superpower
Government has the opportunity to generate more than $1.1 billion in net returns to the economy annually and improve the wellbeing of the nation by investing in adult immunisation.
2.53
The Economic Value of Vaccines
Each $1 invested in boosting access to adult immunisation can deliver more than $3.50 in benefits
Investment in adult vaccination can be Australia’s superpower. Vaccines reduce demands on the health system, increase productivity and benefit the economy.
“Prevention: A Productivity Superpower” assesses the economic value of vaccines. It demonstrates the value of vaccines in boosting productivity while reducing a range of government and social costs: across health, tax, aged care, disability and carer support.
GSK commissioned Evaluate Consulting to explore the cost-effectiveness of those vaccines recommended to Australian adults in the Australian Immunisation Handbook, but not fully funded by the Government.
